EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Targeting Cbl-b in cancer immunotherapy

Ryan C Augustin, Riyue Bao iD, Jason J Luke iD

Journal for ImmunoTherapy of Cancer · 2023-02 · 11 (2) · e006007

DOI: 10.1136/jitc-2022-006007 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 07.02.2023. Verfasst von Ryan C Augustin und 2 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Neoplasms, Lymphoma. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIDCR NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer immunotherapy with immune-checkpoint blockade has improved the outcomes of patients with various malignancies, yet a majority do not benefit or develop resistance. To address this unmet need, efforts across the field are targeting additional coinhibitory receptors, costimulatory proteins, and intracellular mediators that could prevent or bypass anti-PD1 resistance mechanisms. The CD28 costimulatory pathway is necessary for antigen-specific T cell activation, though prior CD28 agonists did not translate successfully to clinic due to toxicity. Casitas B lymphoma-b (Cbl-b) is a downstream, master regulator of both CD28 and CTLA-4 signaling. This E3 ubiquitin ligase regulates both innate and adaptive immune cells, ultimately promoting an immunosuppressive tumor microenvironment (TME) in the absence of CD28 costimulation. Recent advances in pharmaceutical screening and computational biology have enabled the development of novel platforms to target this once ‘undruggable’ protein. These platforms include DNA encoded library screening, allosteric drug targeting, small-interfering RNA inhibition, CRISPR genome editing, and adoptive cell therapy. Both genetic knock-out models and Cbl-b inhibitors have been shown to reverse immunosuppression in the TME, stimulate cytotoxic T cell activity, and promote tumor regression, findings augmented with PD1 blockade in experimental models. In translating Cbl-b inhibitors to clinic, we propose specific gene expression profiles that may identify patient populations most likely to benefit. Overall, novel Cbl-b inhibitors provide antigen-specific immune stimulation and are a promising therapeutic tool in the field of immuno-oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsLymphomaHumansCD28 AntigensProto-Oncogene Proteins c-cblAdaptor Proteins, Signal TransducingImmunotherapyTumor Microenvironment

Stichwörter der Autor:innen

CTLA-4 antigendrug therapy, combinationimmunotherapyreviewtherapies, investigational

Substanzen

CD28 AntigensProto-Oncogene Proteins c-cblAdaptor Proteins, Signal Transducing

Autor:innen und Institutionen

  • UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
  • Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA lukejj@upmc.edu.

ORCID-Profile: Riyue Bao, Jason J Luke

Förderung

  • NCI NIH HHS
  • NIDCR NIH HHS
  • National Institutes of Health

Zitieren

APA

Augustin, R. C., Bao, R., & Luke, J. J. (2023). Targeting Cbl-b in cancer immunotherapy. Journal for ImmunoTherapy of Cancer, 11(2), e006007. https://doi.org/10.1136/jitc-2022-006007

Vancouver

Augustin RC, Bao R, Luke JJ. Targeting Cbl-b in cancer immunotherapy. Journal for ImmunoTherapy of Cancer. 2023;11(2):e006007. doi:10.1136/jitc-2022-006007

BibTeX
@article{Augustin2023,
  author = {Augustin, Ryan C and Bao, Riyue and Luke, Jason J},
  title = {Targeting Cbl-b in cancer immunotherapy},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {2},
  pages = {e006007},
  doi = {10.1136/jitc-2022-006007}
}
Kostenlos starten →